May 10, 2013
/PRNewswire/ -- Elekta (NSE: EKTAb) and Royal Philips Electronics (NYSE: PHG, AEX: PHIA) announced today that Sunnybrook Health Sciences Centre (
) will join their growing consortium to validate the clinical potential of MRI-guided radiation therapy.
Sunnybrook Health Sciences Centre, the sixth largest cancer center in
, is the fourth member to sign the research agreement to evaluate the new technology, which merges radiation therapy and magnetic resonance imaging (MRI) in a single system. Current clinical members of the group include the University Medical Center Utrecht, The
University of Texas
MD Anderson Cancer Center, and The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital.
Integrating an advanced 1.5 Tesla MRI machine with a sophisticated radiation therapy system will provide physicians with exceptional depictions of a patient's soft tissues and tumor and allow them to dynamically track their motion. This breakthrough innovation is designed to permit doctors to deliver radiation in real time under MR guidance for the most precise cancer treatments possible.
"Sunnybrook Health Sciences Centre distinguishes itself in the world of science and medicine by its longstanding dedication of integrating research into clinical domain for the benefit of patients," says
and CEO. "With their international strength in the physical sciences – particularly in imaging technology – and its worldwide repute as a top flight cancer center,
is an ideal partner to help us advance this new technology."
, Vice President, Research at Sunnybrook Health Sciences Centre,
's participation in the research consortium will bring a unique team of physicists, engineers and clinicians to focus on validating the advantages of MRI-guided radiation therapy through technology development and clinical trials.
"We have identified a number of areas to study the value of this technology for patients," he says. "The ultimate goal – acquiring high resolution MRI images of pathology in real time as the radiation is being delivered – could have a dramatic impact on patient health and clinical outcomes."